Sarcopenia and Epidural Steroid Injections in Lumbar Spinal Stenosis
Official title: Association Between Sarcopenia and Outcomes of Interlaminar Epidural Steroid Injection in Patients With Lumbar Spinal Stenosis: A Prospective Observational Study
Run by Marmara University · NCT07855419 · Data updated 2026-11-12
We’re testing how sarcopenia relates to pain, function, and quality of life after a routine interlaminar epidural steroid injection in people with lumbar spinal stenosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 75 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Marmara University Academic / other |
| Locations | 1 site (Istanbul, Istanbul) |
| Status | Recruiting |
| Started | October 2, 2026 |
| Main results expected | March 2027 |
| Study ends | April 2027 |
| Registry record updated | October 7, 2026 |
| Trial ID | NCT07855419 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 50–75 with clinically and radiologically confirmed lumbar spinal stenosis who are scheduled for an interlaminar epidural steroid injection and have MRI data available.
✕Probably not a fit
Patients without sarcopenia or with outcomes not influenced by muscle characteristics may not experience specific benefit from this observational assessment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational study will enroll patients with lumbar spinal stenosis who are planned to receive an interlaminar epidural steroid injection as part of standard care. Before the procedure, researchers will assess sarcopenia using the SARC-F questionnaire, handgrip strength, and the five-times sit-to-stand test, and will review lumbar MRI for paraspinal muscle characteristics and stenosis severity. Outcomes such as pain, functional status, walking ability, and health-related quality of life will be measured at baseline and then again at 3 weeks and 3 months post-injection to see if sarcopenia and muscle characteristics influence these results.
Why it matters
Potential benefit: If sarcopenia is linked to poorer outcomes, this could guide personalized care and rehabilitation strategies after injections.
How similar studies have gone: Prior studies in related contexts suggest muscle mass and function can affect outcomes after spine interventions, but this exact approach is relatively novel in this setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical and radiological diagnosis of lumbar spinal stenosis * Persistent symptoms despite conservative treatment and scheduled to undergo interlaminar epidural steroid injection as part of routine clinical care * Age between 50 and 75 years * Low back and/or leg pain for at least 3 months * Availability of lumbar magnetic resonance imaging (MRI) Exclusion Criteria: * History of lumbar fusion surgery * Lumbar epidural steroid injection within the previous 3 months * Prominent radiculopathy due to lumbar disc herniation * Severe motor deficit or an indication for surgical treatment * Polyneuropathy, neuromuscular disease, or neurological disease that may significantly affect muscle mass * Active malignancy or systemic inflammatory disease * Significant mobility limitation due to advanced hip or knee osteoarthritis * Cognitive impairment or communication problems that may prevent completion of study assessments * Coagulopathy or active infection constituting a contraindication to epidural injection * Inflammatory rheumatic disease requiring chronic corticosteroid therapy
Where it's running
-
Marmara University Pendik Training and Research Hospital
Istanbul, Istanbul, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Konuralp Karbeyaz
- Email: nurbanuhindioglu@gmail.com
- Phone: +90 216 625 45 45
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sarcopenia in Patients After Cardiac Surgery
This observational study tests how common sarcopenia is after cardiac surgery and whether current care helps improve muscle mass and function.
-
Bone marrow mesenchymal stem cell injection for sarcopenia
This study tests whether CG-BM1, a stem cell injection, can be safely given to adults with sarcopenia to see if it helps improve muscle health.
-
GLP-1 receptor agonist use and muscle health in adults with obesity without diabetes
This study tests whether GLP-1 receptor agonists affect muscle mass and strength in adults with obesity who don’t have diabetes.
-
Neuropathic Pain Severity in Lumbar Spinal Stenosis and Its Link to Radiology
This study will test how severe neuropathic pain is in adults with lumbar spinal stenosis and see if it relates to MRI findings and other clinical features.
-
Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients
This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.
-
Lower-limb rehabilitation robot training with nutrition education for sarcopenia
In adults aged 60 and older with sarcopenia, this study tests whether adding robot-assisted leg training to nutrition education can improve muscle mass and walking ability compared with usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.